ProCE Banner Activity

Phase Ib/II CARTITUDE-1 Study of BCMA-Directed CAR T-Cell Therapy JNJ-4528 in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
The BCMA-directed CAR T-cell therapy JNJ-4528 demonstrated manageable safety profile and robust efficacy in heavily pretreated patients with R/R MM.

Released: December 15, 2019

Expiration: December 13, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company